Natixis Advisors LLC Purchases New Position in Enovis Co. (NYSE:ENOV)

Natixis Advisors LLC bought a new position in Enovis Co. (NYSE:ENOV) during the 3rd quarter, Holdings Channel reports. The institutional investor bought 12,680 shares of the company’s stock, valued at approximately $546,000.

A number of other institutional investors have also recently made changes to their positions in the stock. Royce & Associates LP grew its holdings in shares of Enovis by 16.8% during the 3rd quarter. Royce & Associates LP now owns 2,403,685 shares of the company’s stock valued at $103,479,000 after purchasing an additional 346,317 shares during the last quarter. Oppenheimer Asset Management Inc. lifted its position in shares of Enovis by 19.8% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 11,829 shares of the company’s stock worth $509,000 after purchasing an additional 1,953 shares during the period. Victory Capital Management Inc. lifted its position in shares of Enovis by 14.3% in the 3rd quarter. Victory Capital Management Inc. now owns 32,846 shares of the company’s stock worth $1,414,000 after purchasing an additional 4,099 shares during the period. Aigen Investment Management LP lifted its position in Enovis by 5.1% during the 3rd quarter. Aigen Investment Management LP now owns 8,859 shares of the company’s stock valued at $381,000 after acquiring an additional 430 shares during the period. Finally, Chartwell Investment Partners LLC lifted its position in Enovis by 25.6% during the 3rd quarter. Chartwell Investment Partners LLC now owns 201,652 shares of the company’s stock valued at $8,681,000 after acquiring an additional 41,089 shares during the period. Institutional investors own 98.45% of the company’s stock.

Enovis Price Performance

ENOV stock opened at $48.45 on Friday. Enovis Co. has a 52 week low of $38.27 and a 52 week high of $65.03. The company has a quick ratio of 1.12, a current ratio of 2.27 and a debt-to-equity ratio of 0.40. The company has a fifty day simple moving average of $43.01 and a two-hundred day simple moving average of $44.90. The firm has a market capitalization of $2.71 billion, a P/E ratio of -22.12 and a beta of 1.91.

Enovis (NYSE:ENOV) last announced its earnings results on Wednesday, November 6th. The company reported $0.73 earnings per share for the quarter, beating the consensus estimate of $0.62 by $0.11. The business had revenue of $505.22 million for the quarter, compared to the consensus estimate of $504.44 million. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. The business’s revenue for the quarter was up 21.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.56 earnings per share. Analysts anticipate that Enovis Co. will post 2.79 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on ENOV shares. Evercore ISI decreased their target price on shares of Enovis from $62.00 to $58.00 and set an “outperform” rating for the company in a report on Tuesday, October 1st. JPMorgan Chase & Co. reduced their target price on shares of Enovis from $53.00 to $50.00 and set a “neutral” rating for the company in a report on Thursday, August 8th. Needham & Company LLC reaffirmed a “buy” rating and set a $65.00 target price on shares of Enovis in a report on Thursday, November 7th. Finally, JMP Securities initiated coverage on shares of Enovis in a research note on Thursday, October 3rd. They issued an “outperform” rating and a $62.00 price objective for the company. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $67.00.

Enovis Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.